Arcus Biosciences, Summit Therapeutics partner on cancer drug trial for renal cancer

On July 22, Arcus Biosciences and Summit Therapeutics announced a significant clinical trial collaboration to test a combination of their investigational cancer drugs. The trial will evaluate Arcus's casdatifan, a HIF-2α inhibitor, alongside Summit's ivonescimab, a bispecific antibody targeting PD-1 and VEGF. This study will focus on treating clear cell renal cell carcinoma, particularly in patients with first-line metastatic disease. Arcus CEO Terry Rosen emphasized the potential to create a well-tolerated treatment regimen that could extend patient survival and serve as a foundational therapy.

This collaboration comes at a crucial time for both companies as they navigate the competitive landscape of cancer treatment. Arcus aims to bolster its clinical program, while Summit seeks to expand ivonescimab's applications. Under the agreement, Summit will provide ivonescimab, and Arcus will oversee the study, integrating it as a new cohort within its ARC-20 platform. Both firms will share costs and retain commercial rights, with initial trial data expected by mid-2027. Additionally, Arcus has strengthened its strategy by entering a clinical supply agreement with AVEO Oncology on the same day.

Financially, Arcus appears to be in a stronger position compared to Summit. In the second quarter of 2026, Arcus reported revenues of $41 million, albeit down from the previous year, and a net loss of $91 million. The company ended the quarter with $775 million in cash and equivalents, ensuring a cash runway until at least late 2028. Summit, on the other hand, reported no product revenue for the same period and a net loss of $215.7 million, closing the quarter with $690.7 million in cash, heavily supported by recent fundraising efforts. While both companies are free of long-term debt, Arcus's established revenue and extended financial runway place it in a more favorable position.

Looking ahead, the success of this partnership could set new standards in cancer treatment, particularly for renal cell carcinoma. Arcus's casdatifan is gaining attention as a potential backbone therapy, with analysts like Wedbush optimistic about its future, raising the price target to $43. Meanwhile, Summit's ivonescimab is also seen as a promising candidate, especially with its recent expansion into bladder cancer trials. However, both companies must navigate challenges, including cash burn and reliance on clinical milestones, to realize their potential in the evolving oncology market.